NTRK3 and metabolic dysfunction-associated steatohepatitis: Shuang Wang et al. discovered that inhibiting the NTRK3‐NTF3 signalling pathway could inhibit the activation of hepatic stellate cells and reverse NASH fibrosis, suggesting that the autocrine signalling factor NTRK3 was an anti‐fibrosis drug target for NASH.7